NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
This Clinical Perspective provides an update with a focus on nutrition interventions for the three most common dyslipidemias in adults.
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology
Despite the established role of low-density lipoprotein cholesterol (LDL-C) as a major risk factor for cardiovascular disease (CVD), and the persistence of CVD as the…
Understanding Differences in ASCVD Risk and Outcomes in South Asians
A greater prevalence of dyslipidemia, insulin resistance, and atherosclerotic cardiovascular disease (ASCVD) and related-mortality are now well-recognized in South Asians living in the U.S. (SAUS),…
Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force
This scientific statement provides a comprehensive review of the current evidence base available from recent systematic reviews and meta-analyses on the effects of low-CHO and…
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: A consensus statement from the National Lipid Association
Acquisition costs and cost-effectiveness have limited access and recommendations to use proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies (mAbs).
Statins for Primary Prevention in Women: How an Individual-Benefit Model Could Expand Treatment to Hypercholesterolemic Women Under Age 65 with 10-Year ASCVD Risk Less Than 7.5%
Evidence in support of statins for the primary prevention of atherosclerotic cardiovascular disease (ASCVD) in women was sparse until recently.1 However, meta-analyses have documented that…